1-4 of 4
Wan-Ching Yen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A41: Use of patient-derived tumor xenografts (PDX) for discovery and development of an anti-Notch2/3 monoclonal antibody targeting cancer stem cells

Marcus M. Fischer, Wan-Ching Yen, Fumiko Axelrod, Christopher Bond, Jennifer Cain, Belinda Cancilla, Randall Henner, Rene Meisner, Aaron Sato, Jalpa Shaw, Tracy Tang, Breanna Wallace, Min Wang, Chun Zhang, Ann Kapoun, Lei Zhou, Jakob Dupont, John Lewicki, Austin Gurney, Tim Hoey
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): A41.
https://doi.org/10.1158/1557-3265.PDX16-A41
Published: 15 August 2016
View article titled, Abstract A41: Use of patient-derived tumor xenografts (PDX) for discovery and development of an anti-Notch2/3 monoclonal antibody targeting cancer stem cells
Journal Articles

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

Wan-Ching Yen, Marcus M. Fischer, Fumiko Axelrod, Christopher Bond, Jennifer Cain, Belinda Cancilla, William R. Henner, Rene Meisner, Aaron Sato, Jalpa Shah, Tracy Tang, Breanna Wallace, Min Wang, Chun Zhang, Ann M. Kapoun, John Lewicki, Austin Gurney, Timothy Hoey
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (9): 2084–2095.
https://doi.org/10.1158/1078-0432.CCR-14-2808
Published: 30 April 2015
View article titled, Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
Open the PDF for Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency in another window
Includes: Supplementary data
Journal Articles

Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells

Wan-Ching Yen, Marcus M. Fischer, Mark Hynes, Jingjiang Wu, Edward Kim, Lucia Beviglia, V. Pete Yeung, Xiaomei Song, Ann M. Kapoun, John Lewicki, Austin Gurney, Diane M. Simeone, Timothy Hoey
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5374–5386.
https://doi.org/10.1158/1078-0432.CCR-12-0736
Published: 30 September 2012
View article titled, Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
Open the PDF for Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells in another window
Includes: Supplementary data
Journal Articles

A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung Cancer

Wan-Ching Yen, Manny R. Corpuz, Rene Y. Prudente, Tracy A. Cooke, Reid P. Bissonnette, Andrés Negro-Vilar, William W. Lamph
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (24): 8656–8664.
https://doi.org/10.1158/1078-0432.CCR-04-0979
Published: 28 December 2004
View article titled, A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung Cancer
Open the PDF for A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung Cancer in another window